A personalized molecular pathogenesis of MDS

Gustavo Rivero, Steven D. Gore

Research output: Chapter in Book/Report/Conference proceedingChapter


The past few years have witnessed rapid progress in the understanding of disease initiation in MDS. Chromosomal abnormalities are seen in about 50 % of patients, with chromosome 5, 7, 8, 11, and 20 most commonly affected. In those with normal karyotype, evidence of recurrent structural abnormalities is missed even with more sophisticated technology such as single-nucleotide polymorphism array (SNPa). In recent years, molecular alterations have deepened our perception of disease heterogeneity and reinforced the clinical observation that treatment response does not occur in stereotyped patterns. In fact, there is growing and convincing evidence that disease heterogeneity and response to treatment are strongly associated with genotypic and epigenetic abnormalities. Globally, MDS genome is impacted by specific mutations that can be classified as mutations that induce chromatin modification, mutations altering spliceosome machinery, and those affecting oncogenes and tumor suppressor genes. The link between chromosomal abnormalities, mutations, disease phenotype, and patterns of treatment response represents a promising challenge that continues to be unraveled.

Original languageEnglish (US)
Title of host publicationMyelodysplastic Syndromes, Second Edition
PublisherSpringer Berlin Heidelberg
Number of pages13
ISBN (Electronic)9783642362293
ISBN (Print)9783642362286
StatePublished - Jan 1 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A personalized molecular pathogenesis of MDS'. Together they form a unique fingerprint.

Cite this